Oncogenic ZMYND11-MBTD1 fusion protein anchors the NuA4/TIP60 histone acetyltransferase complex to the coding region of active genes.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
14 06 2022
Historique:
received: 07 03 2021
revised: 14 02 2022
accepted: 23 05 2022
entrez: 15 6 2022
pubmed: 16 6 2022
medline: 18 6 2022
Statut: ppublish

Résumé

A recurrent chromosomal translocation found in acute myeloid leukemia leads to an in-frame fusion of the transcription repressor ZMYND11 to MBTD1, a subunit of the NuA4/TIP60 histone acetyltransferase complex. To understand the abnormal molecular events that ZMYND11-MBTD1 expression can create, we perform a biochemical and functional characterization comparison to each individual fusion partner. ZMYND11-MBTD1 is stably incorporated into the endogenous NuA4/TIP60 complex, leading to its mislocalization on the body of genes normally bound by ZMYND11. This can be correlated to increased chromatin acetylation and altered gene transcription, most notably on the MYC oncogene, and alternative splicing. Importantly, ZMYND11-MBTD1 expression favors Myc-driven pluripotency during embryonic stem cell differentiation and self-renewal of hematopoietic stem/progenitor cells. Altogether, these results indicate that the ZMYND11-MBTD1 fusion functions primarily by mistargeting the NuA4/TIP60 complex to the body of genes, altering normal transcription of specific genes, likely driving oncogenesis in part through the Myc regulatory network.

Identifiants

pubmed: 35705031
pii: S2211-1247(22)00729-X
doi: 10.1016/j.celrep.2022.110947
pii:
doi:

Substances chimiques

Cell Cycle Proteins 0
Chromatin 0
Chromosomal Proteins, Non-Histone 0
Co-Repressor Proteins 0
DNA-Binding Proteins 0
MBTD1 protein, human 0
Oncogene Proteins, Fusion 0
ZMYND11 protein, human 0
Histone Acetyltransferases EC 2.3.1.48
Lysine Acetyltransferase 5 EC 2.3.1.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110947

Subventions

Organisme : CIHR
ID : FDN-143314
Pays : Canada
Organisme : CIHR
ID : PJT-378019
Pays : Canada

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Maëva Devoucoux (M)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada.

Victoire Fort (V)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada.

Gabriel Khelifi (G)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada.

Joshua Xu (J)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.

Nader Alerasool (N)

Donnelly Centre for Cellular and Biomolecular Research, Department of Molecular Genetics, University of Toronto, Toronto ON, Canada.

Maxime Galloy (M)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada.

Nicholas Wong (N)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Gaëlle Bourriquen (G)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada.

Amelie Fradet-Turcotte (A)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada.

Mikko Taipale (M)

Donnelly Centre for Cellular and Biomolecular Research, Department of Molecular Genetics, University of Toronto, Toronto ON, Canada.

Kristin Hope (K)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

Samer M I Hussein (SMI)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada. Electronic address: samer.hussein@crchudequebec.ulaval.ca.

Jacques Côté (J)

St. Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Oncology Division of CHU de Québec-Université Laval Research Center, Quebec City, QC G1R 3S3, Canada. Electronic address: jacques.cote@crchudequebec.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH